

Roberto Latagliata

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6100344/roberto-latagliata-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

346
papers

5,275
citations

38
h-index

61
g-index

356
ext. papers

6,047
ext. citations

3.5
avg, IF

4.59
L-index

#	Paper	IF	Citations
346	Utility of procalcitonin and C-reactive protein as predictors of Gram-negative bacteremia in febrile hematological outpatients.. <i>Supportive Care in Cancer</i> , 2022 , 30, 4303	3.9	1
345	Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study.. <i>British Journal of Haematology</i> , 2022 ,	4.5	2
344	Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality. <i>American Journal of Blood Research</i> , 2021 , 11, 417-426	1.6	
343	Nursing Management of Frail Patients with Hematologic Malignancies during COVID-19 Pandemia in the Viterbo Domiciliary Care Unit: Data Analysis from March 2020 to March 2021. <i>Blood</i> , 2021 , 138, 3022-3022	2.2	
342	Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study. <i>Blood</i> , 2021 , 138, 1487-1487	2.2	
341	Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study. <i>Blood</i> , 2021 , 138, 3617-3617	2.2	
340	Hemoglobin Changes during Long-Lasting Frontline Treatment with Tyrosine-Kinase Inhibitors in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2021 , 138, 1486-1486	2.2	
339	Efficacy and Safety of Ruxolitinib in the Treatment of Elderly Patients with Polycythemia Vera Resistant/Intolerant to Hydroxyurea. <i>Blood</i> , 2021 , 138, 2581-2581	2.2	1
338	NGS Evaluation of the Eqol-MDS Trial: Preliminary Analysis of Eltrombopag for Thrombocytopenia of Low-Risk MDS. <i>Blood</i> , 2021 , 138, 1516-1516	2.2	
337	From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox. <i>Frontiers in Oncology</i> , 2021 , 11, 752192	5.3	0
336	COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. <i>British Journal of Haematology</i> , 2021 , 196, 559	4.5	5
335	Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. <i>Hematological Oncology</i> , 2021 , 39, 409-418	1.3	3
334	Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2261-2266	1.9	
333	Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors. <i>Hematological Oncology</i> , 2021 , 39, 401-408	1.3	1
332	Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2021 , 100, 1213-1219	3	2
331	New dead/H-box helicase gene (ddx41) mutation in an Italian family with recurrent leukemia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2280-2283	1.9	2
330	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. <i>Cancer</i> , 2021 , 127, 2657-2665	6.4	7

329	Very late acute myeloid leukemia relapse: clinical features, treatment and outcome. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1022-1025	1.9	1
328	Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, e328-e333	2	
327	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2021 , 193, 356-368	4.5	8
326	Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1026-1027	1.9	2
325	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. <i>Blood Cancer Journal</i> , 2021 , 11, 4	7	16
324	Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols. <i>Acta Oncologica</i> , 2021 , 60, 1520-1526	3.2	0
323	Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study. <i>Acta Oncologica</i> , 2021 , 60, 1527-1533	3.2	0
322	Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia. <i>European Journal of Haematology</i> , 2020 , 105, 286-291	3.8	1
321	Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2020 , 99, 2773-2777	3	1
320	Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. <i>Leukemia</i> , 2020 , 34, 2260-2261	10.7	37
319	PICC-related upper deep venous thrombosis in patients with hematological malignancies. Management of anticoagulant therapy according to the platelet count. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 49, 426-430	5.1	4
318	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. <i>Hematological Oncology</i> , 2020 , 38, 372-380	1.3	7
317	Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1-negative Myeloproliferative Neoplasms Latium Group". <i>European Journal of Haematology</i> , 2020 , 105, 335-343	3.8	1
316	Hematologic alterations and early mortality in a cohort of HIV positive African patients. <i>PLoS ONE</i> , 2020 , 15, e0242068	3.7	2
315	Peripherally inserted central catheters in allogeneic hematopoietic stem cell transplant recipients. <i>Supportive Care in Cancer</i> , 2020 , 28, 4193-4199	3.9	11
314	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. <i>Cancer</i> , 2020 , 126, 1243-1252	6.4	51
313	Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment. <i>Hematological Oncology</i> , 2020 , 38, 189-196	1.3	1
312	SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience. <i>HemaSphere</i> , 2020 , 4, e483	0.3	2

311	Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance. <i>Leukemia and Lymphoma</i> , 2020 , 61, 3476-3483	1.9	0
310	Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience. <i>Annals of Hematology</i> , 2020 , 99, 2405-2416	3	3
309	Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis. <i>Annals of Hematology</i> , 2019 , 98, 1933-1936	3	2
308	Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice. <i>Annals of Hematology</i> , 2019 , 98, 1919-1925	3	8
307	Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life. <i>Annals of Hematology</i> , 2019 , 98, 1891-1904	3	7
306	Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors. <i>Hematological Oncology</i> , 2019 , 37, 291-295	1.3	10
305	Management and outcome of 11 pregnancies in women with polycythemia vera. <i>Leukemia Research</i> , 2019 , 81, 25-26	2.7	2
304	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. <i>Hematological Oncology</i> , 2019 , 37, 418-423	1.3	2
303	Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. <i>Haematologica</i> , 2019 , 104, 1589-1596	6.6	38
302	Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. <i>Annals of Hematology</i> , 2019 , 98, 2329-2338	3	9
301	Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy. <i>Hematological Oncology</i> , 2019 , 37, 447-455	1.3	11
300	Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome. <i>Hematological Oncology</i> , 2019 , 37, 652-654	1.3	10
299	Incidence of Clinically Significant (≥ 10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib. <i>Oncology Research and Treatment</i> , 2019 , 42, 660-664	2.8	0
298	Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial. <i>Blood</i> , 2019 , 134, 3000-3000	2.2	4
297	Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kynase Inhibitors. <i>Blood</i> , 2019 , 134, 1649-1649 ²	2.2	4
296	Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience. <i>Blood</i> , 2019 , 134, 839-839	2.2	2
295	Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence. <i>Blood</i> , 2019 , 134, 4166-4166	2.2	
294	Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement. <i>Blood</i> , 2019 , 134, 3010-3010	2.2	

293	Impact of Comorbidities and Body Mass Index in Patients with Polycythemia Vera: A PV-NET Real World Study. <i>Blood</i> , 2019 , 134, 4184-4184	2.2	
292	Clinical Outcomes Under Hydroxyurea and Impact of ELN Responses in Patients with Polycythemia Vera: A PV-NET Real World Study. <i>Blood</i> , 2019 , 134, 4174-4174	2.2	1
291	Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols. <i>Blood</i> , 2019 , 134, 3845-3845	2.2	1
290	Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?. <i>Leukemia Research</i> , 2019 , 76, 65-69	2.7	3
289	Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations. <i>Blood Reviews</i> , 2019 , 34, 16-25	11.1	10
288	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. <i>Annals of Hematology</i> , 2019 , 98, 889-896	3	4
287	Iron toxicity - Its effect on the bone marrow. <i>Blood Reviews</i> , 2018 , 32, 473-479	11.1	26
286	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. <i>Hematological Oncology</i> , 2018 , 36, 561	1.3	38
285	Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up. <i>Leukemia Research</i> , 2018 , 69, 18-23	2.7	2
284	Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib. <i>British Journal of Haematology</i> , 2018 , 181, 275-278	4.5	2
283	Comparison of JAK2 -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology. <i>Hematological Oncology</i> , 2018 , 36, 269-275	1.3	6
282	Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study. <i>Hematological Oncology</i> , 2018 , 36, 285-290	1.3	19
281	Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. <i>Annals of Hematology</i> , 2018 , 97, 95-100	3	14
280	Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. <i>Annals of Hematology</i> , 2018 , 97, 1797-1802	3	14
279	The IPSS-R has prognostic impact in untreated patients with MDS del(5q). <i>Leukemia Research</i> , 2018 , 72, 27-33	2.7	3
278	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. <i>British Journal of Haematology</i> , 2018 , 183, 35-46	4.5	6
277	Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2018 , 71, 89-91	2.7	0
276	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. <i>Seminars in Hematology</i> , 2018 , 55, 248-255	4	13

275	Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?. <i>European Journal of Haematology</i> , 2018 , 101, 578	3.8	2
274	Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients. <i>Blood</i> , 2018 , 132, 4277-4277	2.2	8
273	Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib. <i>Oncotarget</i> , 2018 , 9, 7534-7540	3.3	10
272	Five Years after Frontline Tyrosine-Kinase Inhibitor (TKI) Treatment Initiation for Chronic Myeloid Leukemia: What Does It Happen in a Real-Life Setting?. <i>Blood</i> , 2018 , 132, 1746-1746	2.2	
271	Presentation and Outcome of 199 Patients with 2016 WHO Diagnosis of Early and Overt Primary Myelofibrosis Treated with Ruxolitinib. <i>Blood</i> , 2018 , 132, 3052-3052	2.2	
270	Identification of Predictive Factors for Overall Survival at Baseline and during Azacitidine Treatment in High-Risk Myelodysplastic Syndromes Treated in the Clinical Practice. <i>Blood</i> , 2018 , 132, 5518-5518	2.2	
269	Overall Survival and Response Rates after a 10-Year Follow-up of Chronic Myeloid Leukemia Patients in Chronic Phase Treated with Imatinib in a Real-Life Practice. <i>Blood</i> , 2018 , 132, 1741-1741	2.2	
268	Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?. <i>Blood</i> , 2018 , 132, 5516-5516	2.2	
267	Frontline Treatment with Dasatinib in Very Elderly Patients (> 75 Years) with Chronic Myeloid Leukemia: Is It Feasible?. <i>Blood</i> , 2018 , 132, 5438-5438	2.2	
266	Real-World Management of Myelofibrosis with Ruxolitinib: Initial Analysis of an Italian Observational Study (ROMEI). <i>Blood</i> , 2018 , 132, 4312-4312	2.2	
265	Management and Outcome of 11 Pregnancies in Women with Polycythemia Vera. <i>Blood</i> , 2018 , 132, 5471-5471	2.2	
264	Real Life Evaluation of Efficacy and Safety of Bosutinib Therapy in Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2018 , 132, 3021-3021	2.2	
263	Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of WHO 2001 Versus WHO 2008/2016 Criteria in a Large Single Center Cohort. <i>Blood</i> , 2018 , 132, 5464-5464	2.2	
262	Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. <i>Leukemia Research</i> , 2018 , 74, 86-88	2.7	14
261	Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events. <i>Annals of Hematology</i> , 2018 , 97, 1803-1808	3.3	8
260	Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a 'real-life' patient population with chronic myeloid leukaemia. <i>Hematological Oncology</i> , 2017 , 35, 232-236	1.3	11
259	Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. <i>Lancet Haematology</i> , 2017 , 4, e127-e136	14.6	95
258	Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia. <i>Cancer Medicine</i> , 2017 , 6, 1233-1239	4.8	6

257	Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life. <i>American Journal of Hematology</i> , 2017 , 92, E668-E670	7.1	4
256	The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017 , 92, E661-E664	7.1	11
255	ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems. <i>American Journal of Hematology</i> , 2017 , 92, 1037-1046	7.1	14
254	High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia. <i>Thrombosis Research</i> , 2017 , 156, 168-171	8.2	7
253	Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. <i>American Journal of Hematology</i> , 2017 , 92, 37-41	7.1	53
252	Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia. <i>Hematological Oncology</i> , 2017 , 35, 804-809	1.3	5
251	Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN. <i>Annals of Hematology</i> , 2017 , 96, 387-391	3	11
250	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. <i>Oncotarget</i> , 2017 , 8, 79073-79086	3.3	38
249	A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2017 , 9, e2017046	3.2	2
248	Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients. <i>American Journal of Hematology</i> , 2016 , 91, 318-21	7.1	19
247	Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response. <i>Leukemia and Lymphoma</i> , 2016 , 57, 99-102	1.9	11
246	JAK2(V617F) allele burden >50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy. <i>Leukemia</i> , 2016 , 30, 1772-5	10.7	38
245	Dasatinib first-line: Multicentric Italian experience outside clinical trials. <i>Leukemia Research</i> , 2016 , 40, 24-9	2.7	4
244	Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis. <i>Blood</i> , 2016 , 128, 1128-1128	2.2	4
243	Incidence of Severe ($\leq 10\text{g/dl}$) Chronic Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib and Role of Erythropoietin Therapy. <i>Blood</i> , 2016 , 128, 1903-1903	2.2	0
242	Incidence of Early Thrombosis in Myeloproliferative Neoplasms (MPN): A Prospective Analysis from the Gruppo Laziale of Ph-Negative MPN. <i>Blood</i> , 2016 , 128, 1951-1951	2.2	2
241	Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis. <i>Blood</i> , 2016 , 128, 4251-4251	2.2	2
240	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. <i>Oncotarget</i> , 2016 , 7, 80083-80090	3.3	21

239	Impact of Comorbidities and Body Mass Index in Myelofibrosis Patients Treated with Ruxolitinib: A Retrospective Analysis. <i>Blood</i> , 2016 , 128, 5464-5464	2.2	
238	Latum (Italy) Epidemiology of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs) from 2011 to 2015: A Prospective Analysis from Gruppo Laziale of Ph Negative MPN. <i>Blood</i> , 2016 , 128, 5473-5473	2.2	
237	Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment. <i>Blood</i> , 2016 , 128, 5544-5544	2.2	1
236	Essential Thrombocythemia: A Comparison of Overall and Thrombosis Free Survival in Two Discrete Periods of the First Decade of 2000. a Retrospective Analysis. <i>Blood</i> , 2016 , 128, 5469-5469	2.2	
235	Deferasirox in the Treatment of Iron Overload during Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2016 , 128, 5465-5465	2.2	
234	Young CML Patients Treated Frontline with Imatinib or Second Generation TKIs: Clinical Characteristics and Outcome. <i>Blood</i> , 2016 , 128, 3078-3078	2.2	
233	Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase. <i>European Journal of Haematology</i> , 2016 , 96, 643-9	3.8	17
232	Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. <i>European Journal of Haematology</i> , 2016 , 96, 344-51	3.8	24
231	Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study. <i>Annals of Hematology</i> , 2016 , 95, 1059-65	3	6
230	The risk of infections in patients with myelodysplastic syndromes in 2016. <i>Expert Review of Hematology</i> , 2016 , 9, 607-14	2.8	8
229	Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. <i>Neoplasia</i> , 2016 , 18, 536-40	6.4	16
228	Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients. <i>American Journal of Hematology</i> , 2015 , 90, E95-6	7.1	
227	Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata. <i>European Journal of Haematology</i> , 2015 , 95, 52-6	3.8	19
226	Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. <i>Leukemia</i> , 2015 , 29, 1344-9	10.7	48
225	Erythropoietin treatment in patients with myelodysplastic syndromes and type 2 diabetes. <i>Journal of Diabetes</i> , 2015 , 7, 493-6	3.8	
224	Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib. <i>American Journal of Hematology</i> , 2015 , 90, 105-8	7.1	8
223	Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>American Journal of Hematology</i> , 2015 , 90, E181-2	7.1	2
222	Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?. <i>Hematological Oncology</i> , 2015 , 33, 48-51	1.3	2

221	Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN. <i>Leukemia Research</i> , 2015 , 39, 801-4	2.7	20
220	Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC). <i>Supportive Care in Cancer</i> , 2015 , 23, 3289-95	3.9	31
219	Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence. <i>Cancer Medicine</i> , 2015 , 4, 1789-97	4.8	14
218	Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2206-7	1.9	5
217	Acute promyelocytic leukemia in patients aged >70 years: the cure beyond the age. <i>Annals of Hematology</i> , 2015 , 94, 195-200	3	12
216	Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis. <i>Leukemia Research</i> , 2015 , 39, 314-7	2.7	10
215	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015 , 26, 185-192	10.3	48
214	Risk Factors for Infections in Myelofibrosis: Role of Disease Status and Treatment. A Study on 507 Patients. <i>Blood</i> , 2015 , 126, 1606-1606	2.2	2
213	Event-Free Survival According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: The Younger, the Later, the Worse?. <i>Blood</i> , 2015 , 126, 4038-4038	2.2	1
212	Cost Description on a Cohort of 659 Patients with Adult MDS Included into the Italian Lazio Region Registry (the GROM-L). <i>Blood</i> , 2015 , 126, 5237-5237	2.2	1
211	Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial. <i>Blood</i> , 2015 , 126, 91-91	2.2	6
210	JAK2V617F-Positive Patients with Essential Thrombocythemia or Early Primary Myelofibrosis: The Impact of Histological Diagnosis on Outcome. <i>Blood</i> , 2015 , 126, 1614-1614	2.2	
209	The Platelet COUNT at Diagnosis of Essential Thrombocythemia Is a Prognostic Factor for Thrombosis-Free Survival: Retrospective Analysis on 1201 Patients. <i>Blood</i> , 2015 , 126, 2815-2815	2.2	
208	Very Elderly Patients with Chronic Phase-Chronic Myeloid Leukemia on Imatinib: No Impact of Concomitant Drugs on Complete Cytogenetic Response. <i>Blood</i> , 2015 , 126, 1582-1582	2.2	
207	Are ET and PV Patients Two Similar Populations As Concern Thrombotic Risk Factors?. <i>Blood</i> , 2015 , 126, 2811-2811	2.2	
206	Application of the International Prognostic Score of Thrombosis for Essential Thrombocythemia(ET) (IPSET-Thrombosis) in a Cohort of ET Patients: Experience from Gruppo Laziale for Myeloproliferative Ph Negative Neoplasms. <i>Blood</i> , 2015 , 126, 2821-2821	2.2	
205	Long-Term Follow-up in Very Elderly Patients with Chronic Myeloid Leukemia Treated with Imatinib Frontline. <i>Blood</i> , 2015 , 126, 1598-1598	2.2	
204	Second-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukaemia (CML). <i>BioDrugs</i> , 2014 , 28, 17-26	7.9	21

203	Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study. <i>Annals of Hematology</i> , 2014 , 93, 1413-20	3	3
202	Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile. <i>American Journal of Hematology</i> , 2014 , 89, 565	7.1	2
201	Thrombosis and survival in essential thrombocythemia: a regional study of 1,144 patients. <i>American Journal of Hematology</i> , 2014 , 89, 542-6	7.1	24
200	Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. <i>Leukemia Research</i> , 2014 , 38, 1173-6	2.7	22
199	Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocytic leukemia cells. <i>Annals of Hematology</i> , 2014 , 93, 1819-23	3	15
198	Pregnancy in acute promyelocytic leukaemia after front-line therapy with arsenic trioxide and all-trans retinoic acid. <i>British Journal of Haematology</i> , 2014 , 167, 428-30	4.5	3
197	Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients. <i>Leukemia Research</i> , 2014 , 38, 194-7	2.7	17
196	Prognostic Factors for Thrombosis-Free Survival and Overall Survival in Polycytemia Vera: A Retrospective Analysis of 623 Patients Series with Long Follow-up. <i>Blood</i> , 2014 , 124, 1855-1855	2.2	
195	Real-life Frontline Dasatinib Treatment in Unselected Elderly Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2014 , 124, 5530-5530	2.2	
194	The Experience of Gruppo Laziale for the Study of Ph-, Chronic Myeloproliferative Syndromes in the Treatment of Myeloproliferative Neoplasms in Blastic Phase with Azacytidine. <i>Blood</i> , 2014 , 124, 3164-3164	2.2	1
193	Independent Prognostic Impact of CD15 for Achievement of Complete Remission in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2014 , 124, 3687-3687	2.2	
192	Incidence of Infectious Complications in MDS/AML Patients Treated with Azacitidine By the Italian Cooperative Groups Gruppo Romano MDS (GROM) and Basilicata MDS Registry. <i>Blood</i> , 2014 , 124, 3265-3265	2.2	
191	Role of CD133 As a Marker of Previous Myelodysplasia in De Novo Elderly Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2014 , 124, 1063-1063	2.2	
190	Mutations and Long-Term Outcome of 217 Young Patients with Essential Thrombocythemia or Early Primary Myelofibrosis. <i>Blood</i> , 2014 , 124, 3190-3190	2.2	
189	Acute Myeloid Leukemia Patients with an Undefined Genetic Profile at Diagnosis: Clinical and Prognostic Aspects. <i>Blood</i> , 2014 , 124, 5326-5326	2.2	
188	Hematological Improvement during Deferasirox Treatment in Patients with Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2014 , 124, 3189-3189	2.2	
187	Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. <i>Hematological Oncology</i> , 2013 , 31, 103-9	1.3	44
186	Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study. <i>Drugs and Aging</i> , 2013 , 30, 629-37	4.7	29

185	Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. <i>Annals of Hematology</i> , 2013 , 92, 179-83	3	8
184	Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study. <i>Annals of Hematology</i> , 2013 , 92, 25-32	3	20
183	Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2458-65	1.9	22
182	Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib. <i>Cancer Letters</i> , 2013 , 333, 32-5	9.9	13
181	Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). <i>Journal of Clinical Oncology</i> , 2013 , 31, 4424-30	2.2	61
180	Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols. <i>Leukemia Research</i> , 2013 , 37, 383-5	2.7	3
179	Management of acute promyelocytic leukemia in the elderly. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013 , 5, e2013045	3.2	5
178	Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia. <i>Acta Haematologica</i> , 2013 , 129, 126-34	7	5
177	Cardiovascular events and intensity of treatment in polycythemia vera. <i>New England Journal of Medicine</i> , 2013 , 368, 22-33	59.2	506
176	Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2671-7	2.2	97
175	FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis. <i>Haematologica</i> , 2013 , 98, e161-3	6.6	37
174	Exclusion Criteria In The Dasision and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of a Real-life Patient Population With Chronic Myelogenous Leukemia?. <i>Blood</i> , 2013 , 122, 4002-4002	2.2	0
173	FLT3-ITD Internal Tandem Duplication Confers Poor Prognosis In Patients With Acute Promyelocytic Leukemia Treated With The AIDA Protocols. Long-Term Follow-Up Analysis. <i>Blood</i> , 2013 , 122, 1336-1336	2.2	
172	Real-Life Efficacy Of Azacitidine In Myelodysplastic Syndromes According To IPSS Cytogenetic Profile. <i>Blood</i> , 2013 , 122, 5229-5229	2.2	
171	Deferasirox In The Treatment Of Iron Overload During Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2013 , 122, 1594-1594	2.2	
170	Prognostic Factors Associated To Achievement Of Complete Or Partial Response In MDS Patients Treated With Azacitidine Outside Clinical Trials. <i>Blood</i> , 2013 , 122, 5203-5203	2.2	
169	Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug. <i>Cancer</i> , 2012 , 118, 404-9	6.4	30
168	Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion. <i>Annals of Hematology</i> , 2012 , 91, 309-10	3	2

167	The EUTOS score identifies chronic myeloid leukaemia patients with poor prognosis treated with imatinib first or second line. <i>Leukemia Research</i> , 2012 , 36, e209-10	2.7	17
166	Prognostic features of patients with myelodysplastic syndromes aged Leukemia and Lymphoma, 2012 , 53, 2439-43	1.9	6
165	Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population. <i>Annals of Hematology</i> , 2012 , 91, 1345-9	3	28
164	Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. <i>Blood</i> , 2012 , 119, 49-54	2.2	52
163	Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. <i>Haematologica</i> , 2012 , 97, 560-7	6.6	54
162	How Epidemiology of Polycythemia Vera Has Changed in the Last 10 Years: Results From the Whole Prospective Cohort of Patients in Cyto-PV Trial As Compared with Eclap Prospective Cohort. <i>Blood</i> , 2012 , 120, 1748-1748	2.2	1
161	A Large-Scale Trial Testing the Intensity of Cytoreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera (CYTO-PV trial). <i>Blood</i> , 2012 , 120, 4-4	2.2	2
160	Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS). <i>Blood</i> , 2012 , 120, 923-923	2.2	10
159	The Role of Previous Thrombotic Events in Patients with Essential Thrombocythemia: The Earlier the Worse?. <i>Blood</i> , 2012 , 120, 5062-5062	2.2	
158	Response to Erythropoietin in a Multicentric Real-Life Cohort of Myelodysplastic Patients: The Grom Experience. <i>Blood</i> , 2012 , 120, 4958-4958	2.2	
157	Delayed Cytogenetic Response and Reduced Rate of Major Molecular Response Associated to Increased Body Mass Index At Baseline in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib.. <i>Blood</i> , 2012 , 120, 2784-2784	2.2	
156	Incidence of Late Chronic Anemia in Newly Diagnosed Patients with Chronic Myelogenous Leukemia Responsive to Imatinib. <i>Blood</i> , 2012 , 120, 3769-3769	2.2	
155	Long-Term Follow-up of Chronic Phase Chronic Myeloid Leukemia Patients Who Failed Interferon Alpha and Switched to Imatinib. <i>Blood</i> , 2012 , 120, 3742-3742	2.2	
154	AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. <i>Blood</i> , 2011 , 117, 4716-25	2.2	147
153	Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia. <i>Haematologica</i> , 2011 , 96, 1390-1	6.6	16
152	Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. <i>Haematologica</i> , 2011 , 96, 1457-61	6.6	49
151	Suboptimal response to imatinib according to 2006-2009 European LeukaemiaNet criteria: a 'grey zone' at 3, 6 and 12 months identifies chronic myeloid leukaemia patients who need early intervention. <i>British Journal of Haematology</i> , 2011 , 152, 119-21	4.5	8
150	GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. <i>British Journal of Haematology</i> , 2011 , 154, 564-8	4.5	22

149	Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. <i>Leukemia Research</i> , 2011 , 35, 1164-9	2.7	25
148	Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. <i>Leukemia Research</i> , 2011 , 35, 159-62	2.7	33
147	Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes. <i>Leukemia Research</i> , 2011 , 35, 504-7	2.7	11
146	Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide. <i>Leukemia Research</i> , 2011 , 35, e69-70	2.7	2
145	Familial occurrence of myelodysplastic syndrome with del(5q). <i>Leukemia and Lymphoma</i> , 2011 , 52, 1143-5.9		
144	Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians. <i>Haematologica</i> , 2011 , 96, 696-702	6.6	51
143	Unexpected erythroid and cytogenetic responses after discontinuation of a short course of lenalidomide as a result of severe skin rash in a patient with 5q syndrome. <i>Journal of Clinical Oncology</i> , 2011 , 29, e402-3	2.2	5
142	Management of the 2009 A/H1N1 influenza pandemic in patients with hematologic diseases: a prospective experience at an Italian center. <i>Acta Haematologica</i> , 2011 , 126, 1-7	2.7	5
141	Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (. <i>Blood</i> , 2011 , 118, 2770-2770	2.2	1
140	Treatment with Erythropoietic Stimulating Agents in IPSS Lower Risk MDS: Outcome Comparison Between 5q- and Non 5q- MDS Cases. <i>Blood</i> , 2011 , 118, 2799-2799	2.2	1
139	Complete Cytogenetic Response After 3 Months Is a Very Early Indicator of Good Response to Imatinib As Front-Line Treatment in Chronic Myelogenous Leukemia,. <i>Blood</i> , 2011 , 118, 3783-3783	2.2	2
138	MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients,. <i>Blood</i> , 2011 , 118, 3793-3793	2.2	
137	Moderate/ Severe Pleural Effusion As a Side Effect in Very Old Chronic Myeloid Leukemia (CML) Patients Undergoing Imatinib Treatment. <i>Blood</i> , 2011 , 118, 4445-4445	2.2	
136	Clinical Follow-up of Patients with Myeloproliferative Neoplasms Presenting Skin Ulcers During Treatment with Hydroxyurea. <i>Blood</i> , 2011 , 118, 5157-5157	2.2	
135	Clinical Features of Idiopathic Erythrocytosis Compared to Polycythemia Vera JAK-2 V617F Positive and Negative Patients. <i>Blood</i> , 2011 , 118, 5172-5172	2.2	
134	APPLICATION of EUTOS SCORE IN CHRONIC Myeloid LEUKEMIA AFFECTING VERY Elderly (>75 years) PATIENTS. <i>Blood</i> , 2011 , 118, 1686-1686	2.2	
133	Risk Factors for Thrombosis Vary According to Age in Patients with Essential Thrombocythemia: a Retrospective Analysis of 1090 Patients from the Gruppo Laziale SMPC Ph Negative □ <i>Blood</i> , 2011 , 118, 3854-3854	2.2	
132	Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Eelderly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival. <i>Blood</i> , 2011 , 118, 2751-2751	2.2	1

131	Increased Body Mass Index Correlates with Higher Risk of Disease Relapse and Differentiation Syndrome in Patients with Acute Promyelocytic Leukemia Treated with Aida Protocols. <i>Blood</i> , 2011 , 118, 4866-4866	2.2	
130	Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients. <i>Leukemia and Lymphoma</i> , 2010 , 51, 783-8	1.9	15
129	Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1007-14	1.9	31
128	Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose. <i>Hematological Oncology</i> , 2010 , 28, 89-92 ¹⁻³		10
127	Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation. <i>Haematologica</i> , 2010 , 95, 853-4	6.6	37
126	Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion. <i>European Journal of Haematology</i> , 2010 , 85, 231-5	3.8	22
125	Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up. <i>American Journal of Hematology</i> , 2010 , 85, 375-7	7.1	6
124	Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. <i>Leukemia Research</i> , 2010 , 34, 143-7	2.7	26
123	"Real-life" results of front-line treatment with Imatinib in older patients (≥5 years) with newly diagnosed chronic myelogenous leukemia. <i>Leukemia Research</i> , 2010 , 34, 1472-5	2.7	41
122	Low-Dose Dasatinib as Front-Line Therapy for Elderly (> 60 Years) Patients with CML. <i>Blood</i> , 2010 , 116, 2293-2293	2.2	2
121	Increases In Mirna-145 and Mirna-146a Expression In Patients with IPSS Lower-Risk Myelodysplastic Syndromes and Del(5q) Treated with Lenalidomide.. <i>Blood</i> , 2010 , 116, 3631-3631	2.2	1
120	Myelodysplastic Syndrome Patients Younger Than 50 Years: Epidemiological Data and Clinical Features. <i>Blood</i> , 2010 , 116, 4976-4976	2.2	
119	Retrospective Application of European LeukemiaNet Provisional Criteria for Second-Generation TKI Chronic Myeloid Leukemia. <i>Blood</i> , 2010 , 116, 2270-2270	2.2	
118	Hammersmith Score Is Able to Identify Chronic Myeloid Leukemia Patients with Poor Prognosis Before Treatment with Second-Generation TKIs.. <i>Blood</i> , 2010 , 116, 3409-3409	2.2	0
117	Skin Toxicity of Hydroxyurea In Ph- Myeloproliferative Neoplasms: Incidence and Clinical Features. <i>Blood</i> , 2010 , 116, 3077-3077	2.2	
116	Bone Marrow Immunological Changes During Treatment with Lenalidomide In Low and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5Q). <i>Blood</i> , 2010 , 116, 2927-2927	2.2	
115	A Retrospective Epidemiological Analysis of 1572 Cases of Ph1- Myeloproliferative Neoplasms (MPNs) From 9 Centers In the Latium: Preliminary Results. <i>Blood</i> , 2010 , 116, 5065-5065	2.2	
114	Imatinib In Very Elderly CML Patients: What Can We Achieve?.. <i>Blood</i> , 2010 , 116, 1229-1229	2.2	

113	Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry. <i>American Journal of Hematology</i> , 2009 , 84, 636-40	7.1	61
112	Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients. <i>Hematological Oncology</i> , 2009 , 27, 148-53	1.3	37
111	Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results. <i>International Journal of Hematology</i> , 2009 , 90, 486-491	2.3	1
110	Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal. <i>Leukemia Research</i> , 2009 , 33, 391-4	2.7	3
109	Dasatinib in the management of lymphoid blast crisis of Philadelphia-positive chronic myeloid leukemia with multiple extra-medullary and intracranial localizations. <i>Leukemia Research</i> , 2009 , 33, e134-6	2.7	12
108	ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS AGED > 70 Years.. <i>Blood</i> , 2009 , 114, 4160-4160	2.2	
107	The Dose and the duration of frontline therapy with Imatinib does not affect response to Dasatinib in Imatinib-Resistant or -intolerant patients with chronic myeloid leukemia (CML). Results from a real Life-Based Italian Multicenter retrospective study on 124 Patients.. <i>Blood</i> , 2009 , 114, 1124-1124	2.2	
106	Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia: How Important is the Achievement of Complete Cytogenetic Response after 3 Months?. <i>Blood</i> , 2009 , 114, 4271-4271	2.2	
105	Clinical Usefulness and Safety of Peripherally-Inserted Central Catethers (PICC) in Hematological Patients.. <i>Blood</i> , 2009 , 114, 4545-4545	2.2	
104	Clinical Results in Patients with Primary and Secondary Myelofibrosis Treated with Monthly Cycles of Oral Melphalan.. <i>Blood</i> , 2009 , 114, 4985-4985	2.2	
103	Gene Expression Changes in Bone Marrow of MDS Patients with Del(5q) During Lenalidomide Treatment.. <i>Blood</i> , 2009 , 114, 2622-2622	2.2	
102	Lenalidomide for the Treatment of Low- and Int-1-Risk MDS with Del(5q): Efficacy and Quality of Life Study.. <i>Blood</i> , 2009 , 114, 2763-2763	2.2	1
101	Real-Life Analysis of Dasatinib in Chronic Phase CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib.. <i>Blood</i> , 2009 , 114, 2211-2211	2.2	
100	Minor Erythroid Response and Decreased WT1 Expression After Proteasome Inhibition by Bortezomib in Myelodysplastic Syndromes (GIMEMA MDS0104 Phase II Trial).. <i>Blood</i> , 2009 , 114, 1777-1777	2.2	
99	Results of Imatinib Dose Escalation After 36 Months of Follow-up in Chronic Myeloid Leukemia Patients with Failure or Sub-Optimal Response According to 2006 European Leukemia Net (ELN) Criteria.. <i>Blood</i> , 2009 , 114, 3302-3302	2.2	
98	Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. <i>British Journal of Haematology</i> , 2008 , 143, 681-9	4.5	50
97	Negative impact of FLT3 abnormalities in elderly acute myeloid leukemia patients. <i>Leukemia and Lymphoma</i> , 2008 , 49, 994-7	1.9	8
96	Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2008 , 49, 2328-32	1.9	8

95	Twice-weekly high-dose rHuEpo for the treatment of anemia in patients with low-risk myelodysplastic syndromes. <i>Acta Haematologica</i> , 2008 , 120, 104-7	2.7	15
94	Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin. <i>Haematologica</i> , 2008 , 93, 1918-20	6.6	15
93	Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenetic response after interferon-alpha results in a very high complete molecular response rate. <i>Leukemia Research</i> , 2008 , 32, 255-61	2.7	11
92	Ocular side effects in chronic myeloid leukemia patients treated with imatinib. <i>Leukemia Research</i> , 2008 , 32, 1022-5	2.7	30
91	Pregnancy in patients with myelodysplastic syndromes (MDS). <i>Leukemia Research</i> , 2008 , 32, 1605-7	2.7	4
90	Circulating MUC1 Levels (CA15.3) in Myeloproliferative Disorders (MPD). <i>Blood</i> , 2008 , 112, 5237-5237	2.2	1
89	Dasatinib in the Treatment of CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib. <i>Blood</i> , 2008 , 112, 4253-4253	2.2	
88	Cytoreductive Combined Therapy in Essential Thrombocythemia Patients: Report of the Registro Italiano Trombocitemia (RIT). <i>Blood</i> , 2008 , 112, 5243-5243	2.2	
87	Cytoreductive Therapeutic Approach in the Essential Thrombocythemia (ET) Patients of the Registro Italiano Trombocitemia (RIT): Preliminary Data. <i>Blood</i> , 2008 , 112, 5248-5248	2.2	
86	Quality of Life Scores Have a Prognostic Significance In Elderly AML Patients.. <i>Blood</i> , 2008 , 112, 1949-1949	2.2	
85	Differences in Haematological and Non Haematological Toxicity during Treatment with Imatinib in Early and Late Chronic Phase Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2008 , 112, 4281-4281	2.2	
84	Prognostic Relevance of Retrospective WHO Re-Classification in 650 MDS Patients Diagnosed by FAB Criteria. <i>Blood</i> , 2008 , 112, 5097-5097	2.2	
83	Comorbidities and FLT3 Abnormalities as Independent Prognostic Indicators of Survival in Elderly Acute Myeloid Leukemia Patients. <i>Blood</i> , 2008 , 112, 3983-3983	2.2	
82	Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. <i>Leukemia Research</i> , 2007 , 31, 1770-2	2.7	49
81	Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. <i>Leukemia</i> , 2007 , 21, 79-83	10.7	88
80	Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia. <i>Annals of Hematology</i> , 2007 , 86, 263-70	3	20
79	Refractory anaemia with excess of blasts in transformation re-evaluated with the WHO criteria: identification of subgroups with different survival. <i>Acta Haematologica</i> , 2007 , 117, 221-5	2.7	3
78	Late relapses in acute promyelocytic leukaemia. <i>Acta Haematologica</i> , 2007 , 117, 106-8	2.7	14

77	Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. <i>Haematologica</i> , 2007 , 92, 101-5	6.6	49
76	JAK2 (V617F) Mutation Levels and Marrow Fibrosis in Patients Affected by Budd-Chiari Syndrome and Non-Cirrhotic Extra-Hepatic Portal Vein Obstruction.. <i>Blood</i> , 2007 , 110, 4652-4652	2.2	
75	Changes in Gene Expression Profiles during Treatment with Erythropoetic Growth Factors in Myelodysplastic Syndromes.. <i>Blood</i> , 2007 , 110, 4609-4609	2.2	
74	Favourable Outcome of Pregnancy in Essential Thrombocythemia (ET) Patients Treated with Interferon Alpha. A Report from the Registro Italiano Trombocitemia (RIT).. <i>Blood</i> , 2007 , 110, 2549-2549 ^{2,2}		
73	Decisional Flow with a Score System To Start Platelet-Lowering Treatment in Patients with Essential Thrombocythemia (ET): Long-Term Results.. <i>Blood</i> , 2007 , 110, 4636-4636	2.2	
72	Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon. <i>Annals of Oncology</i> , 2006 , 17, 281-5	10.3	27
71	Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2006 , 30, 178-82	2.7	12
70	Long Term Follow-Up of the Gimema GSI 103 AMLE Randomized Trial: Daunoxome Seems To Improve Disease-Free Survival (DFS) of Elderly Patients with Acute Myelogenous Leukemia (AML).. <i>Blood</i> , 2006 , 108, 1979-1979	2.2	4
69	Risk Factors for Cardiovascular Events in Myeloproliferative Syndromes.. <i>Blood</i> , 2006 , 108, 3595-3595	2.2	
68	Quality of Life in Elderly Patients with Acute Myeloid Leukemia.. <i>Blood</i> , 2006 , 108, 3320-3320	2.2	
67	Impact of Age in the Outcome of Patients with Chronic Myeloid Leukemia in Late Chronic Phase: Clinical and Molecular Results of a Phase II Study of the GIMEMA CML Working Party.. <i>Blood</i> , 2006 , 108, 4805-4805	2.2	
66	Imatinib Mesylate Therapy in Late Ph+ Chronic Myeloid Leukemia Patients in Stable Complete Cytogenetic Response after Interferon-Alpha Results in a Very High Complete Molecular Response Rate.. <i>Blood</i> , 2006 , 108, 2158-2158	2.2	
65	Darbepoetin for the Treatment of Anemia of Myelodysplastic Syndromes: Efficacy and Improvements in Quality of Life.. <i>Blood</i> , 2006 , 108, 2667-2667	2.2	1
64	Identification of risk factors in atypical chronic myeloid leukemia. <i>Haematologica</i> , 2006 , 91, 1566-8	6.6	70
63	Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation. <i>Leukemia Research</i> , 2005 , 29, 33-9	2.7	8
62	Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment. <i>Leukemia Research</i> , 2005 , 29, 287-91	2.7	19
61	Myelodysplastic syndromes in patients under 50 years old: a single institution experience. <i>Leukemia Research</i> , 2005 , 29, 749-54	2.7	19
60	BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results. <i>Bone Marrow Transplantation</i> , 2005 , 36, 83-4	4.4	4

59	Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib. <i>European Journal of Haematology</i> , 2005 , 74, 89-90	3.8	39
58	Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. <i>European Journal of Haematology</i> , 2005 , 74, 121-3	3.8	53
57	Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. <i>Annals of Hematology</i> , 2005 , 84, 167-76	3	89
56	PEG Intron Treatment in 90 Patients with Essential Thrombocythemia (ET) Final Report of a Phase II Study.. <i>Blood</i> , 2005 , 106, 2600-2600	2.2	1
55	Bone Marrow Evaluation According to the PVSG and WHO Criteria in 90 Essential Thrombocythemia (ET) Patients Treated with PEG Interferon alpha-2b. Preliminary Results.. <i>Blood</i> , 2005 , 106, 4962-4962	2.2	0
54	Therapy-Related Myelodysplastic Syndrome (sMDS) /Acute Myelogenous Leukemia (sAML) in Acute Promyelocytic Leukemia (APL) Patients with Long-Lasting Molecular Remission: The GIMEMA Experience.. <i>Blood</i> , 2005 , 106, 884-884	2.2	
53	Long-Term Results of the GIMEMA LAP AIDA 0493 Amended Protocol in Elderly Patients with Acute Promyelocytic Leukemia (APL).. <i>Blood</i> , 2005 , 106, 885-885	2.2	
52	Increased Risk of Thrombotic Events in Patients with Acute Promyelocytic Leukemia (APL) Receiving ATRA Treatment: Does It Correlate with CD2 and FLT3 Expression?.. <i>Blood</i> , 2005 , 106, 887-887 ^{2.2}		
51	Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia. <i>Leukemia</i> , 2004 , 18, 182	10.7	15
50	Apoptosis susceptibility and cell-cycle distribution in cells from myelodysplastic syndrome patients: modulatory in-vitro effects of G-CSF and interferon-alpha. <i>Leukemia and Lymphoma</i> , 2004 , 45, 1437-43	1.9	1
49	Bone Marrow Biopsy and Aspirate Evaluation in 90 Patients with Essential Thrombocythemia Treated with PEG Interferon alpha-2b. Preliminary Results.. <i>Blood</i> , 2004 , 104, 1523-1523	2.2	4
48	Association of Hydroxyurea to Imatinib Is Effective in Patients with Chronic Myelogenous Leukemia Resistant to Imatinib Alone.. <i>Blood</i> , 2004 , 104, 4693-4693	2.2	1
47	Survival of elderly patients with acute myeloid leukemia. <i>Haematologica</i> , 2004 , 89, 296-302	6.6	39
46	Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia. <i>Haematologica</i> , 2004 , 89, 615-7	6.6	12
45	Prognostic factors in myelodysplastic and myeloproliferative types of chronic myelomonocytic leukemia: a retrospective analysis of 83 patients from a single institution. <i>Haematologica</i> , 2004 , 89, 866-8	6.6	23
44	A long-term study of young patients with essential thrombocythemia treated with anagrelide. <i>Haematologica</i> , 2004 , 89, 1306-13	6.6	36
43	High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias. <i>Annals of Hematology</i> , 2003 , 82, 476-480	3	8
42	Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen. <i>Leukemia</i> , 2003 , 17, 925-30	10.7	28

41	Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. <i>Leukemia</i> , 2003 , 17, 1085-90	10.7	60
40	Conservative treatment for patients over 80 years with acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2002 , 71, 256-9	7.1	10
39	Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 2002 , 116, 576-81	4.5	71
38	Intracardiac thrombus in a patient with autoimmune hemolytic anemia leading to a diagnosis of antiphospholipid syndrome. <i>Acta Haematologica</i> , 2002 , 107, 170-2	2.7	3
37	Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. <i>Blood</i> , 2002 , 99, 822-4	2.2	110
36	Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. <i>Blood</i> , 2002 , 100, 2703-7	2.2	97
35	Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. <i>Blood</i> , 2002 , 100, 2980-8	2.2	219
34	Intraventricular thrombosis during all-trans retinoic acid treatment in acute promyelocytic leukemia. <i>Leukemia</i> , 2001 , 15, 1311-3	10.7	17
33	Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsed from first complete remission. <i>Haematologica</i> , 2001 , 86, 814-20	6.6	16
32	Spontaneous remission in adult patients with de novo myelodysplastic syndrome: a possible event. <i>Haematologica</i> , 2001 , 86, 1277-80	6.6	12
31	Molecular and cytogenetic remission in a case of subtype M4E acute myelogenous leukemia with minimal monochemotherapy: high sensitivity or spontaneous remission?. <i>European Journal of Haematology</i> , 2000 , 65, 203-6	3.8	7
30	Treatment of long-lasting priapism in chronic myeloid leukemia at onset. <i>Annals of Hematology</i> , 2000 , 79, 644-5	3	20
29	Acute myeloblastic leukemia secondary to myelodysplasia (MDS-AML): a comparison of remission induction with three drugs versus standard two-drugs induction. <i>Leukemia and Lymphoma</i> , 2000 , 36, 539-41	1.9	1
28	Granulocytic sarcoma with breast and skin presentation: a report of a case successfully treated by local radiation and systemic chemotherapy. <i>Acta Haematologica</i> , 2000 , 104, 34-7	2.7	13
27	A case-control study of the effects of hydroxyurea on circulating cortisol levels in patients with acute myelogenous leukemia and chronic myeloproliferative disorders. <i>Pharmacological Research</i> , 2000 , 42, 389-92	10.2	0
26	Coronary thrombotic events in acute promyelocytic leukemia during all-trans retinoic acid treatment: a role for adhesion molecules overexpression?. <i>Leukemia</i> , 1999 , 13, 312-3	10.7	10
25	Outpatient management of acute promyelocytic leukemia after consolidation chemotherapy. <i>Leukemia</i> , 1999 , 13, 514-7	10.7	17
24	Acute myeloid leukemia in the elderly: 'per aspera ad astra'?. <i>Leukemia Research</i> , 1999 , 23, 603-13	2.7	17

23	Out-patient management of acute myeloid leukemia after consolidation chemotherapy. Role of a hematologic emergency unit. <i>Haematologica</i> , 1999 , 84, 814-9	6.6	25
22	Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991). <i>Leukemia</i> , 1998 , 12, 869-74	10.7	31
21	Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. <i>American Journal of Hematology</i> , 1998 , 58, 105-9	7.1	95
20	Cytotoxic effectors activated by low-dose IL-2 plus IL-12 lyse IL-2-resistant autologous acute myeloid leukaemia blasts. <i>British Journal of Haematology</i> , 1998 , 101, 150-7	4.5	15
19	Etoposide, intermediate-dose cytarabine and carboplatin (VAC): a combination therapy for the blastic phase of chronic myelogenous leukemia. <i>Annals of Oncology</i> , 1997 , 8, 175-9	10.3	8
18	The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged > 60 years. <i>Annals of Oncology</i> , 1997 , 8, 1273-5	10.3	20
17	Management of infective complications in patients with advanced hematologic malignancies in home care. <i>Leukemia</i> , 1997 , 11, 1807-12	10.7	22
16	Simultaneous occurrence of large B-cell non-Hodgkin lymphoma and myelodysplastic syndrome rapidly evolving into acute myeloblastic leukemia. <i>Leukemia and Lymphoma</i> , 1996 , 21, 339-41	1.9	5
15	Treatment of high-risk myelodysplastic syndromes with lymphoblastoid alpha interferon. <i>British Journal of Haematology</i> , 1996 , 95, 364-7	4.5	9
14	Is aggressive chemotherapy the best choice for patients with acute nonlymphocytic leukemia after myelodysplastic syndromes?. <i>Leukemia Research</i> , 1995 , 19, 213-7	2.7	3
13	MEC (mitoxantrone, etoposide and intermediate dose cytarabine): an effective induction regimen for previously untreated acute non-lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 1995 , 19, 447-51	1.9	6
12	Is recombinant human erythropoietin treatment in myelodysplastic syndromes worthwhile?. <i>Leukemia and Lymphoma</i> , 1993 , 9, 79-83	1.9	17
11	Bisantrene in relapsed and refractory acute myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 1993 , 9, 217-20	1.9	3
10	Polycythaemia vera and cerebral blood flow: a preliminary study with transcranial Doppler. <i>Journal of Internal Medicine</i> , 1993 , 234, 599-602	10.8	15
9	Erythropoietin treatment of idiopathic myelofibrosis. <i>Haematologica</i> , 1993 , 78, 371-3	6.6	12
8	Recombinant human erythropoietin in the treatment of myelodysplastic syndromes. An interim report. <i>Haematologica</i> , 1993 , 78, 123-6	6.6	4
7	Mitoxantrone, etoposide and intermediate-dose Ara-C (MEC): an effective regimen for poor risk acute myeloid leukemia. <i>Leukemia</i> , 1993 , 7, 549-52	10.7	44
6	A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA. <i>European Journal of Cancer & Clinical Oncology</i> , 1991 , 27, 750-5		84

5	Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. <i>British Journal of Haematology</i> , 1990 , 75, 4-9	4.5	152
4	High doses of ara-C and m-AMSA in the treatment of refractory acute non lymphocytic leukemia. <i>Haematologica</i> , 1990 , 75, 249-51	6.6	4
3	CD7 positive acute myeloid leukaemia: a subtype associated with cell immaturity. <i>British Journal of Haematology</i> , 1989 , 73, 480-5	4.5	87
2	Immunophenotyping of acute myeloid leukaemia: relevance of analysing different lineage-associated markers. <i>Blut</i> , 1989 , 58, 235-40		25
1	Acute nonlymphocytic leukemia in the elderly: results of a retrospective study. <i>Haematologica</i> , 1989 , 74, 167-71	6.6	7